PMC:7555630 / 9737-10481 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T11","span":{"begin":346,"end":352},"obj":"Body_part"}],"attributes":[{"id":"A11","pred":"fma_id","subj":"T11","obj":"http://purl.org/sig/ont/fma/fma264279"}],"text":"Mortality in this series was thirteen out of thirty-six patients (36%). Of the patients who died, twelve (92%) were greater than 60 years old, eleven (85%) had parkinsonism, eleven (85%) were from an extended care facility, nine (69%) had comorbid dementia, nine (69%) had at least one high-risk comorbid condition, eight (62%) had alteration in mental status as a presenting symptom, and eight (62%) received a medication with antiviral properties (hydroxychloroquine, oseltamivir, amantadine, and memantine), including three who were on an adamantane prior to contracting COVID-19. Looking specifically at the patients in our cohort with parkinsonism, versus those without parkinsonism, their outcomes are separated out and shown in Figure 1."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T90","span":{"begin":248,"end":256},"obj":"Disease"},{"id":"T91","span":{"begin":574,"end":582},"obj":"Disease"}],"attributes":[{"id":"A90","pred":"mondo_id","subj":"T90","obj":"http://purl.obolibrary.org/obo/MONDO_0001627"},{"id":"A91","pred":"mondo_id","subj":"T91","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Mortality in this series was thirteen out of thirty-six patients (36%). Of the patients who died, twelve (92%) were greater than 60 years old, eleven (85%) had parkinsonism, eleven (85%) were from an extended care facility, nine (69%) had comorbid dementia, nine (69%) had at least one high-risk comorbid condition, eight (62%) had alteration in mental status as a presenting symptom, and eight (62%) received a medication with antiviral properties (hydroxychloroquine, oseltamivir, amantadine, and memantine), including three who were on an adamantane prior to contracting COVID-19. Looking specifically at the patients in our cohort with parkinsonism, versus those without parkinsonism, their outcomes are separated out and shown in Figure 1."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T42","span":{"begin":66,"end":68},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T43","span":{"begin":363,"end":364},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T44","span":{"begin":410,"end":411},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Mortality in this series was thirteen out of thirty-six patients (36%). Of the patients who died, twelve (92%) were greater than 60 years old, eleven (85%) had parkinsonism, eleven (85%) were from an extended care facility, nine (69%) had comorbid dementia, nine (69%) had at least one high-risk comorbid condition, eight (62%) had alteration in mental status as a presenting symptom, and eight (62%) received a medication with antiviral properties (hydroxychloroquine, oseltamivir, amantadine, and memantine), including three who were on an adamantane prior to contracting COVID-19. Looking specifically at the patients in our cohort with parkinsonism, versus those without parkinsonism, their outcomes are separated out and shown in Figure 1."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T13","span":{"begin":428,"end":437},"obj":"Chemical"},{"id":"T14","span":{"begin":450,"end":468},"obj":"Chemical"},{"id":"T15","span":{"begin":470,"end":481},"obj":"Chemical"},{"id":"T16","span":{"begin":483,"end":493},"obj":"Chemical"},{"id":"T17","span":{"begin":499,"end":508},"obj":"Chemical"},{"id":"T18","span":{"begin":542,"end":552},"obj":"Chemical"}],"attributes":[{"id":"A13","pred":"chebi_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A14","pred":"chebi_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A15","pred":"chebi_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A16","pred":"chebi_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/CHEBI_2618"},{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_64312"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_40519"}],"text":"Mortality in this series was thirteen out of thirty-six patients (36%). Of the patients who died, twelve (92%) were greater than 60 years old, eleven (85%) had parkinsonism, eleven (85%) were from an extended care facility, nine (69%) had comorbid dementia, nine (69%) had at least one high-risk comorbid condition, eight (62%) had alteration in mental status as a presenting symptom, and eight (62%) received a medication with antiviral properties (hydroxychloroquine, oseltamivir, amantadine, and memantine), including three who were on an adamantane prior to contracting COVID-19. Looking specifically at the patients in our cohort with parkinsonism, versus those without parkinsonism, their outcomes are separated out and shown in Figure 1."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T65","span":{"begin":160,"end":172},"obj":"Phenotype"},{"id":"T66","span":{"begin":248,"end":256},"obj":"Phenotype"},{"id":"T67","span":{"begin":640,"end":652},"obj":"Phenotype"},{"id":"T68","span":{"begin":675,"end":687},"obj":"Phenotype"}],"attributes":[{"id":"A65","pred":"hp_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/HP_0001300"},{"id":"A66","pred":"hp_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/HP_0000726"},{"id":"A67","pred":"hp_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/HP_0001300"},{"id":"A68","pred":"hp_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/HP_0001300"}],"text":"Mortality in this series was thirteen out of thirty-six patients (36%). Of the patients who died, twelve (92%) were greater than 60 years old, eleven (85%) had parkinsonism, eleven (85%) were from an extended care facility, nine (69%) had comorbid dementia, nine (69%) had at least one high-risk comorbid condition, eight (62%) had alteration in mental status as a presenting symptom, and eight (62%) received a medication with antiviral properties (hydroxychloroquine, oseltamivir, amantadine, and memantine), including three who were on an adamantane prior to contracting COVID-19. Looking specifically at the patients in our cohort with parkinsonism, versus those without parkinsonism, their outcomes are separated out and shown in Figure 1."}

{"project":"LitCovid-sentences","denotations":[{"id":"T66","span":{"begin":0,"end":71},"obj":"Sentence"},{"id":"T67","span":{"begin":72,"end":583},"obj":"Sentence"},{"id":"T68","span":{"begin":584,"end":744},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Mortality in this series was thirteen out of thirty-six patients (36%). Of the patients who died, twelve (92%) were greater than 60 years old, eleven (85%) had parkinsonism, eleven (85%) were from an extended care facility, nine (69%) had comorbid dementia, nine (69%) had at least one high-risk comorbid condition, eight (62%) had alteration in mental status as a presenting symptom, and eight (62%) received a medication with antiviral properties (hydroxychloroquine, oseltamivir, amantadine, and memantine), including three who were on an adamantane prior to contracting COVID-19. Looking specifically at the patients in our cohort with parkinsonism, versus those without parkinsonism, their outcomes are separated out and shown in Figure 1."}

{"project":"LitCovid-PubTator","denotations":[{"id":"322","span":{"begin":56,"end":64},"obj":"Species"},{"id":"323","span":{"begin":79,"end":87},"obj":"Species"},{"id":"324","span":{"begin":612,"end":620},"obj":"Species"},{"id":"325","span":{"begin":0,"end":9},"obj":"Disease"},{"id":"326","span":{"begin":92,"end":96},"obj":"Disease"},{"id":"327","span":{"begin":160,"end":172},"obj":"Disease"},{"id":"328","span":{"begin":248,"end":256},"obj":"Disease"},{"id":"329","span":{"begin":574,"end":582},"obj":"Disease"},{"id":"330","span":{"begin":640,"end":652},"obj":"Disease"},{"id":"331","span":{"begin":675,"end":687},"obj":"Disease"}],"attributes":[{"id":"A322","pred":"tao:has_database_id","subj":"322","obj":"Tax:9606"},{"id":"A323","pred":"tao:has_database_id","subj":"323","obj":"Tax:9606"},{"id":"A324","pred":"tao:has_database_id","subj":"324","obj":"Tax:9606"},{"id":"A325","pred":"tao:has_database_id","subj":"325","obj":"MESH:D003643"},{"id":"A326","pred":"tao:has_database_id","subj":"326","obj":"MESH:D003643"},{"id":"A327","pred":"tao:has_database_id","subj":"327","obj":"MESH:D010302"},{"id":"A328","pred":"tao:has_database_id","subj":"328","obj":"MESH:D003704"},{"id":"A329","pred":"tao:has_database_id","subj":"329","obj":"MESH:C000657245"},{"id":"A330","pred":"tao:has_database_id","subj":"330","obj":"MESH:D010302"},{"id":"A331","pred":"tao:has_database_id","subj":"331","obj":"MESH:D010302"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Mortality in this series was thirteen out of thirty-six patients (36%). Of the patients who died, twelve (92%) were greater than 60 years old, eleven (85%) had parkinsonism, eleven (85%) were from an extended care facility, nine (69%) had comorbid dementia, nine (69%) had at least one high-risk comorbid condition, eight (62%) had alteration in mental status as a presenting symptom, and eight (62%) received a medication with antiviral properties (hydroxychloroquine, oseltamivir, amantadine, and memantine), including three who were on an adamantane prior to contracting COVID-19. Looking specifically at the patients in our cohort with parkinsonism, versus those without parkinsonism, their outcomes are separated out and shown in Figure 1."}